Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News

Stay up to date with the exciting new developments as we continue to grow.

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Filter by date

1 May 2020

Shield Therapeutics plc – Business and Trading Update

Shield Therapeutics plc, provides a business and unaudited trading update, to view the full update please click here.

22 Apr 2020

Directorate Change

Shield Therapeutics plc, announces that, following discussions with major shareholders and with mutual agreement, Carl Sterritt has informed the Company of his decision to resign…

17 Mar 2020

AEGIS-H2H study update

Shield Therapeutics plc, today provides an update and clarification relating to the AEGIS-H2H clinical trial, the data from which was primarily designed to be used…

8 Jan 2020

Shield Therapeutics announces exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd in China.

Shield Therapeutics plc,  announces that it has entered into an exclusive licence agreement for its lead product Feraccru®/Accrufer® (ferric maltol) with Beijing Aosaikang Pharmaceutical Co.…

26 Sep 2019

Investor Presentation

Shield Therapeutics plc, announces that the Company will be hosting an investor presentation on Tuesday 12 November 2019. For further information click here.  

29 Aug 2019

Investor presentations

Shield Therapeutics plc, announces that the Company will be presenting at the following investor forums, providing an opportunity for investors to hear about the progress…

7 Aug 2019

Interim Report for the six months ended 30 June 2019

Shield Therapeutics plc, announces its unaudited interim results for the six months ended 30 June 2019. For further details please click here.

26 Jul 2019

FDA approves Feraccru® with a broad label of treating iron deficiency in adults

For further details please click here.

13 Jun 2019

Result of Shield Therapeutics plc – 2019 AGM

Shield Therapeutics plc, announces the results of the proxy vote for each of the resolutions set out in the Notice of AGM. Further details can…